RCA
HAE icon

Rowland Carmichael Advisors’s Haemonetics HAE Stock Holding History

Rowland Carmichael Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$703K Buy
+5,917
New +$637K 0.22% 102
2018
Q2 		– Sell
-3,680
Closed -$269K – 357
2018
Q1 		$269K Hold
3,680
– – 0.15% 192
2017
Q4 		$214K Buy
+3,680
New +$194K 0.11% 237

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Rowland Carmichael Advisors's HAE Position: Q4 2020 in Review

Rowland Carmichael Advisors opened a new position in Haemonetics (HAE) in Q4 2020: 5,917 shares worth $703K. The stake represents 0.22% of the portfolio and ranks #102 among its holdings. This is a return to the name: Rowland Carmichael Advisors previously reported a position in HAE as recently as Q1 2018.

Rowland Carmichael Advisors first reported a position in HAE in Q4 2017 and has held it in 3 quarters since. 286 funds tracked by Wall St. Rank hold HAE as of Q4 2020.

  • Rowland Carmichael Advisors held 5,917 shares of Haemonetics worth $703K as of Q4 2020.
  • Haemonetics was a new Rowland Carmichael Advisors position in Q4 2020.
  • Haemonetics made up 0.22% of Rowland Carmichael Advisors's portfolio in Q4 2020, its #102 holding.
  • Rowland Carmichael Advisors first reported a position in Haemonetics in Q4 2017 and has held it in 3 quarters since.
  • 286 funds tracked by Wall St. Rank held Haemonetics as of Q4 2020.

Based on Rowland Carmichael Advisors's 13F filing for Q4 2020, filed 15 Jan 2021.